Clinical Courses of Schizophrenia

Abstract

Schizophrenia is a complex disorder, characterized by molecular, neuroendocrine, and behavioral alterations as well as gene-environment interactions. This article summarizes key facts on the diagnosis, long-term course and neurocognitive deficits of schizophrenia. Due to the heterogeneity of schizophrenia with regard to symptomatology, illness manifestations, course and outcome, the focus of attention has shifted from diagnostic categories to endophenotypes which are hoped to characterize distinct subtypes of schizophrenia more appropriately than the diagnostic classification systems. The systems approach aims to assess the complexity and multiple dynamics of biological systems to explain endophenotypes of schizophrenia and their associations with susceptibility genes. Data presented in this paper support the view that looking for associations between neurocognitive endophenotypes and susceptibility genes might be a promising approach for future research to elucidate the heterogeneity of schizophrenic spectrum disorders.

Key words

schizophrenia - endophenotypes - follow-up - heterogeneity - neurocognitive functioning - outcome

• References

• 1 Huber G, Gross G, Schüttler R et al. Longitudinal studies of schizophrenic patients. Schizophr Bull 1980; 6: 592-605
• 2 Bleuer M. Die Schizophrenen Geistesstörungen im Lichte langjähriger Kranken- und Familiengeschichten. Stuttgart: Thieme; 1972
• 3 van Os J, Kapur S. Schizophrenia. Lancet 2009; 374: 635-645
• 4 Watt DC, Katz K, Shepherd M. The natural history of schizophrenia: a 5-year prospective follow-up a representative sample of schizophrenics by means of a standardized clinical and social assessment. Psychological Med 1983; 13: 663-670
• 5 Albus M, Hubmann W, Mohr F et al. Neurocognitive functioning in patients with first-episode schizophrenia: results of a prospective 5-year follow-up study. Eur Arch Psychiatry Clin Neurosci 2006; 256: 442-451
• 6 Albus M. Symptomatik und Verlauf schiophrener Erkrankungen. In: Becker T, Bäuml J, Pitschel-Walz G, Weig W. (eds.). Rehabilitation bei schizophrenen Erkrankungen. Deutscher Ärzteverlag; Köln: 2007: 25-38
• 7 Eaton WW, Thara R, Federman E et al. Remission and relapse in schizophrenia: the Madras longitudinal study. J Nerv Ment Dis 1998; 186: 357-363
• 8 Wiersma D, Nienhuis FJ, Slooff CJ et al. Natural course of schizophrenic disorders: A 15-year follow-up of a Dutch incidence cohort. Schizophr Bull 1998; 24: 75-85
• 9 Ciompi L, Müller C. Lebensweg und Alter der Schizophrenen. Eine katamnestische Langzeitstudie bis ins Senium. Springer; Berlin, Heidelberg, New York: 1976
• 10 Harrow M, Grossman LS, Jobe TH et al. Do patients with schizophrenia ever have periods of recovery? A 15-year multi-follow-up study. Schizophrenia Bull 2005; 31: 723-734
• 11 Shepherd M, Watt D, Falloon IRH et al. The natural history of schizophrenia: A five-year follow-up Study of outcome and prediction in a representative sample of schizophrenics. Cambridge University Press; Cambridge: 1989
• 12 Rosen K, Garety P. Predicting recovery from schizophrenia. A retrospective comparison of characteristics at onset of people with single and multiple episodes. Schizophrenia Bull 2005; 31: 735-750
• 13 Bottlender R, Wegner U, Wittmann J et al. Phänomenologie des Verlaufs schizophrener Erkrankungen: Ergebnisse aus der Münchner 15-Jahres-Verlaufsstudie funktioneller Psychosen. In: Soyka M, Möller H-J, Wittchen H-U. (eds.). Psychopathologie im Längsschnitt. Ecomed; Landsberg: pp 113-126 2003
• 14 Sellwood W, Wittkowski A, Tarrier N et al. Needs-based cognitive behavioral family intervention for patients suffering from schizophrenia: 5-year follow-up of a randomized controlled effectiveness trial. Acta Psych Scand 2007; 116: 447-452
• 15 Albus M, Hubmann W, Wahlheim C et al. contrasts in neuropsychological test profile between patients with first-episode schizophrenia and first-episode affective disorders. Acta Psychiatr Scand 1996; 94: 87-93
• 16 Doyle A, Wildenauer DB, Albus M et al. The genetic association of AKT1 single nucleotide polymorphisms with schizophrenia and neurocognitive endophenotypes. submitted